TradingMenu expanded
Forge Markets Browse Companies
DataMenu expanded
Forge Data IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Reports Private Market Data & Analytics Startup News
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Browse Companies
Data Menu expandedData
Forge Data
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Reports
Private Market Data & Analytics
Startup News
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Companies / Hemab Therapeutics Stock

Hemab Therapeutics Stock

hemab.comHealthcareFounded: 2022

Hemab Therapeutics, founded in 2019, specializes in developing treatments for patients with bleeding and thrombotic disorders. Specifically, the company focuses on finding preventive treatments for less-common disorders for which fewer treatments are currently available. The company’s therapies are designed to accumulate, modulate, and make use of endogenous clotting factors in patients to form hemostatic plugs when it matters most.

Buy or sell Hemab Therapeutics stockLearn more about Hemab Therapeutics IPO
Register for Details

For more details on financing and valuation for Hemab Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Hemab Therapeutics.

Register Today

Hemab Therapeutics investors also invested in these private companies

Ra Capital Management
Rock Springs Capital
Novo Holdings
The Invus Group
Deep Track Capital
Access Biotechnology
Avoro Ventures
Maj Invest
BioInnovation Institute
HealthCap

Team

Management Team

Benny Sørensen Ph.D
Chief Executive Officer
Mads Behrndt
Chief Financial Officer
Johan Faber Ph.D
Co-Founder & Chief Technology Officer
Thomas Stenfeldt
Co-Founder

Board Members

Camilla Hansen Ph.D
Novo Holdings
Dan Becker Ph.D
Access Biotechnology
Uya Chuluunbaatar Ph.D
Avoro Ventures

Other companies like Hemab Therapeutics in the Healthcare sector

Neuralink
Sector
Healthcare
Last Round Est. Valuation
$2.15B
Colossal Biosciences
Sector
Healthcare
 
 
Altos Labs
Sector
Healthcare
Last Round Est. Valuation
$3.67B
Synchron
Sector
Healthcare
Last Round Est. Valuation
$400.53MM
Grail
Sector
Healthcare
Last Round Est. Valuation
$4.26B
OURA
Sector
Healthcare
 
 
Mammoth Biosciences
Sector
Healthcare
Last Round Est. Valuation
$1.08B
Cytonics
Sector
Healthcare
 
 
Precision Neuroscience
Sector
Healthcare
 
 

News

FIERCE BIOTECH 02/21/2023
With $135M in fresh funds, Hemab aims to leapfrog drug development for neglected blood disorders
While hemophilia has soaked up clinical attention and investor dollars for decades, it’s come at the expense of a range of intriguingly named but less well-known blood clotting disorders. That’s where Hemab Therapeutics comes in.
PR NEWSWIRE 01/10/2023
Hemab Therapeutics Announces First Patient Dosed in Phase 1/2 Study of HMB-001 to Treat Bleeding Disorder Glanzmann Thrombasthenia
Hemab Therapeutics, a clinical-stage biotechnology company developing next-generation therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the first patient has been dosed in a Phase 1/2 study evaluating HMB-001 for the treatment of the severe bleeding disorder Glanzmann Thrombasthenia (Glanzmann).

Trending Companies

Frequently Asked Questions